FINWIRES · TerminalLIVE
FINWIRES

Sirnaomics Doses First Patient in Fat-Reduction Drug Trial

By

Sirnaomics (HKG:2257) dosed the first patient in a phase II clinical trial of STP705 for aesthetic applications, according to a Thursday Hong Kong bourse filing.

The product has been developed to deliver a minimally-invasive therapeutic alternative to conventional fat-reduction interventions.

Related Articles